Joseph Kueter, MD
Urology · Jonesboro, ARNPI 1053383174
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $18,312 of the $21,104 with a category attached, or 86.8%. Ozark Cryosurgery, LLC accounts for 86.8% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $9,081 and has fallen 95.6% since, to $399 in 2025.
Across 125 payments — averaging $168.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ozark Cryosurgery, LLC$18K
- Boston Scientific$324
- AbbVie$319
- Coloplast$312
- Astellas Pharma US Inc$199
- Medtronic$168
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,79213%
- Ownership interest$18,31287%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ozark Cryosurgery, LLC | 3 | $18,312 |
| Boston Scientific | 11 | $324 |
| AbbVie(2 entities) | 17 | $319 |
| Coloplast | 16 | $312 |
| Astellas Pharma US Inc | 15 | $199 |
| Medtronic(2 entities) | 7 | $168 |
| Intuitive Surgical | 2 | $166 |
| Myriad Genetic Laboratories, Inc. | 4 | $139 |
| Pfizer | 3 | $120 |
| Dendreon Pharmaceuticals LLC | 6 | $111 |
| Sumitomo Pharma America, Inc. | 6 | $106 |
| Myovant Sciences Inc. | 7 | $105 |
| Blue Earth Diagnostics | 5 | $90 |
| Procept Biorobotics Corporation | 3 | $79 |
| Baxter Healthcare | 1 | $78 |
| Koelis Inc. | 1 | $74 |
| Johnson & Johnson | 1 | $65 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $50 |
| Conmed Corporation | 1 | $49 |
| Urogen Pharma, Inc. | 3 | $45 |
| Axonics, Inc. | 3 | $44 |
| Olympus America Inc. | 2 | $32 |
| Laborie Medical Technologies Corp. | 1 | $24 |
| Amgen | 1 | $19 |
| Biocompatibles, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Civco Medical Instruments | 1 | $16 |
| Angiodynamics, Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,104 in reported general payments places this provider in the 80th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 129 | $74,653 |
| GemtesaVibegron | 50 | $25,671 |
| Tamsulosin Hcl | 190 | $2,981 |
| Imipramine Hcl | 93 | $1,938 |
| Testosterone Cypionate | 36 | $1,817 |
| Trospium Chloride | 29 | $1,731 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 102 | $1,721 |
| Potassium Citrate ErPotassium Citrate | 19 | $1,547 |
| Finasteride | 136 | $1,479 |
| Bicalutamide | 63 | $1,310 |
| Bethanechol Chloride | 18 | $979 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 31 | $922 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 18 | $915 |
| Solifenacin Succinate | 56 | $886 |
| Cefdinir | 57 | $791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $199 | $74,653129 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $106 | $25,67150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 88 urology providers in Arkansas.
Other urology in Jonesboro
- Emily JacobsJonesboro$37K
- Rudolph BowensJonesboro$21K
- Ladd ScriberJonesboro$7K
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Ronald KuhnNorth Little Rock$138K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Kevin ClaybrookLittle Rock$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.